Thrombocythemia
Oncology·MeSH: Thrombocytosis
Prevalence
30.0 / 100K
10 drugs in development·6 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| vonjo | CTI BIOPHARMA CORP (CTIC) |
Phase 3(3)
Phase 2(3)
Phase 1(1)
| Drug | Company |
|---|---|
| inca033989 | Incyte Corp. (INCY) |
Preclinical(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Thrombocythemia?
BioSniper tracks 10 drugs in development for Thrombocythemia across 6 companies.
How many clinical trials target Thrombocythemia?
There are 1 clinical trial targeting Thrombocythemia tracked by BioSniper.
What is the prevalence of Thrombocythemia?
The estimated prevalence of Thrombocythemia is approximately 30.0 per 100,000 population.
Deep-dive into Thrombocythemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis